Wegovy prescribing information sheet. Medicine information.

Wegovy prescribing information sheet 5 mg, and 1 mg new safety information. Costing information Based on the NICE Resource Impact Template for NICE TA875, the estimated cost of implementing this guidance is HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. After a 3-month (12-week) screening period in which each participant received behavioral lifestyle therapy (counseling about healthy nutrition and physical activity), participants were then randomly assigned to two groups. WEGOVY® (semaglutide) injection, for subcutaneous use Initial U. It has the smallest size and Please see additional Important Safety Information throughout. PAY $25 *Eligibility and restrictions apply. Wegovy Recommended Dosage. Wegovy has become one of the most popular FDA-approved treatments for weight management. These highlights do not include all the information needed to use Aranesp safely and effectively. 2 beats per minute from baseline were observed with patients taking Wegovy ® Cardiovascular Risk Reduction . Prescribing Information Sheet, November 2020 This document provides general prescribing information on the use of Semaglutide. Unlike all other GLP-1 analogs, Semaglutide is 94% identical to the natural endogenous GLP-1. 75 mL 0169-4525-14 0169-4505-14 These highlights do not include all the information needed to use MOUNJARO safely and effectively. 7 mg solution for injection These highlights do not include all the information needed to use WEGOVY safely and effectively. The information referred to may not comply with Australian regulatory requirements. 7 mg • n I your fifth month, you’ll increase your weekly dose to 2. What is Wegovy™? Wegovy™ (semaglutide) injection 2. This information does not replace talking to your healthcare provider about your medical condition or treatment. If you are worried about using this medicine, speak to your doctor or pharmacist. Weeks 9 through 12 = 1 mg once weekly. 7 mg and 2. 2 (obesity), or For more information about using Wegovy, see the package leaflet or contact your healthcare provider. 4 mg (recommended) or 1. Continue reading Scroll to ISI What is Wegovy ®?. to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight The most common side effects of Wegovy ® may include nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat. Keep this Discover information, education and resources for Wegovy® (semaglutide 2. Tell your health care professional if you have any Suitable for prescribing in primary care following recommendation or initiation by a specialist. If patients do not tolerate the maintenance 2. 5mg weekly; Week 9 to week 12: 1mg weekly; Week 13 to week 16: What to know about prescribing Wegovy™ How to prescribe once-weekly Wegovy™ Wegovy™ comes in 5 packs (one for each strength). Store the Wegovy single-dose pen in the refrigerator from 2°C to 8°C (36°F to 46°F). 1 . This medicine is subject to additional monitoring. It is not known if Wegovy™ will cause thyroid tumors or a type of thyroid cancer called Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2. 25 mg injected subcutaneously once-weekly and follow the dose escalation schedule below to minimize gastrointestinal adverse reactions. In other words, Wegovy is a high-dose injectable Semaglutide, like Ozempic, that is administered weekly. If needed, storage between 46°F and 86°F (8°C and 30°C) is permissible for up to 28 days. If you have any questions about your prescription please contact your prescriber. RYBELSUS (semaglutide) tablets, for oral use Initial U. WARNING: RISK OF THYROID C-CELL TUMORS . All medicines A-Z. Wegovy Injections are similar to Ozempic injections except that the dose of Semaglutide administered is high when Wegovy is used. Wegovy ® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines. 25 mg once weekly for 4 weeks. Wegovy® is an injectable prescription drug that is FDA-approved and clinically proven to help with weight loss. Inject subcutaneously in the abdomen, thigh or upper arm (2. Cancel Contact us. It is not known if Wegovy ® is safe and effective for use in children under 12 years of age. It is to be injected subcutaneously in the abdomen, in the thigh or in the upper arm. It may have been superseded. The 0. 25 mg, 0. 4mg) for overweight and obesity. (4). 25 mg per week; Escalate the patient’s Wegovy ® dose every 4 weeks; Please refer to the Prescribing Information for full dosing information; If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. Wegovy ® (semaglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass Wegovy is administered once weekly at any time of the day, with or without meals. See full prescribing information for complete boxed warning. It is not known if Wegovy® (semaglutide) will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Week 1 to week 4: 0. Dosing with Wegovy™ • Start Wegovy™ with a dose of 0. As for all medicines, data on the use of Wegovy are continuously monitored. semaglutide . This Vaccine Information Fact Sheet contains information to help you understand the risks and benefits of COMIRNATY (COVID-19 Vaccine, mRNA),the Pfizer-BioNTech COVID-19 Vaccine, and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent, which you may receive because there is currently a pandemic of COVID-19. Wegovy® and Ozempic® both contain the same active ingredient, semaglutide. Scroll to ISI What is Ozempic ®?. 4 weekly. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for complete boxed warning. Currently Wegovy ® (semaglutide) is available to patients 12 years of age and above. • 1. • • RECENT MAJOR Refer to Instructions for Use within the Prescribing Information for how to use the Wegovy® pen. 0%) Wegovy ®-treated patients were between 65 and 74 years of age and 23 (1%) were ≥ 75 years of age. In studies with rodents, Wegovy™ and medicines that work like Wegovy™ caused thyroid tumors, including thyroid cancer. Find out side effects, medicine names, dosages and uses. 7 mg FlexTouch ® solution for injection in pre-filled pen Highlights of the Article. 25 mg solution for injection in pre-filled pen . It is available as an injection. OZEMPIC® (semaglutide) injection, for subcutaneous use Initial U. Kushner RF, Calanna S, Davies M, et al. 5 mg/0. Wegovy® 1 mg FlexTouch® solution for injection in pre-filled pen . 1 INDICATIONS . Important Safety Information What are the possible side effects of Wegovy®? (cont’d) Wegovy® may cause serious side effects, including: (cont’d) • kidney problems (kidney failure). It belongs to a group of drugs that copy a hormone in your body to help control appetite and how much food you eat. MOUNJARO® (tirzepatide) Injection, for subcutaneous use Initial U. • • RECENT MAJOR Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2. wegovy - Free download as PDF File (. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for Prescribing Information & Safety Data Sheets Submit a Question Search the Exchange. 0. It has gained attention for its ability to support lasting weight loss when combined with a healthy diet and regular exercise. Do not use Wegovy™ if particulate matter or colouration Wegovy is administered once weekly at any time of the day, with or without meals. WEGOVY (semaglutide) injection, for subcutaneous use Initial U. 4 mg Prescribing Information For more information about the dose escalation schedule for Wegovy ®, please see the Prescribing Information. Created Date: 12/13/2023 10:35:37 PM The Department of Health and Social Care have produced some public facing information on accessing semaglutide for weight loss: Accessing Wegovy for weight loss: Everything you need to know. com, you can edit, sign, share, and download the Wegovy Medication Information for Safe Use along with hundreds of thousands of other documents. 4 mg is an injectable prescription medicine that may help adults with obesity (BMI ≥30) or some adults with excess weight (BMI ≥27) These highlights do not include all the information needed to use WEGOVY safely and effectively. 9% over 68 weeks, significantly higher than the 2. In patients with type 2 diabetes, monitor blood glucose prior to starting and during WEGOVY treatment (2. 7 mg solution for injection See full prescribing information for WEGOVY. Instructions for use Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2. 4 mg for your maintenance dose. References to depression and suicidal thoughts have not substantially changed. 25 mg once a week for four weeks, and then your Wegovy dose will increase every 4 weeks until you reach a maintenance dose of 1. Semaglutide 2. 1)]: • 230 kg/m or greater (obesity) or These highlights do not include all the information needed to use WEGOVY ® safely and effectively. and it is advisable to check with local pharmacies or healthcare providers for accurate pricing information. 31 March 2021. Active ingredients. [1-2] Semaglutide was initially approved as a treatment for type 2 diabetes, but studies have found that GLP-1 drugs At PrintFriendly. Medicine information. Further information relevant to the Australian environment is available from Novo Nordisk (Australia) or via What is the most important information I should know about Wegovy®? (cont’d) Wegovy® may cause serious side effects, including: (cont'd) •Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine were randomized to receive either Wegovy™ (reduced calorie meal plan and increased physical activity) or placebo (reduced calorie meal plan and increased physical activity only), and evaluated over a 68-week period. 3. 5 mg, 1 mg, 1. Saxenda ® should be inspected for changes such as precipitation, or change in color or clarity that may indicate a Suitable for prescribing in primary care following recommendation or initiation by a specialist. 5 mL 0. wegovy is a medicine for weight loss and weight maintenance that contains the active substance semaglutide. See full prescribing information for OZEMPIC ®. Approval: 2017 See full prescribing information for complete boxed warning. Wegovy ® 0. Prescribing Strength NDC Days Supply Dispense Quantity Recommended SIG 0. Ozempic ® (semaglutide) injection 0. See full prescribing information for Aranesp. Approval: 2017 Scroll to ISI What is Wegovy ®?. 4 mg. C. Wegovy should Wegovy ® contains the active ingredient semaglutide. See full prescribing information for OZEMPIC. 8 months). Date registered. Decision date. Wegovy® should be used along with a reduced calorie diet and increased physical activity. Renewal PA requests require the member to be taking an appropriate maintenance dose, as outlined in the Wegovy prescribing information. The WEGOVY pen is for subcutaneous (under the skin) use only. Weeks 13 through 16 = 1. 7-clean Page 1 of 29 AusPAR - Wegovy - semaglutide - PM-2021-00612-1-5 - Novo Nordisk Pty Ltd Date of Finalisation 4 September 2024. For the most up to date information, consult the summary of product characteristics For information on Bedfordshire and Luton Joint Prescribing Committee (JPC) recommendations on Wegovy package insert / prescribing information for healthcare professionals. PharmaCare's drug coverage decision for semaglutide \(Wegovy\) Keywords These highlights do not include all the information needed to use WEGOVY safely and effectively. Subscribe to updates; Contact us; Facebook (Twitter) Youtube new safety information. 17 KB] Device/Product Name. Talk to your These highlights do not include all the information needed to use WEGOVY safely and effectively. Read this Instructions for Use before you start using WEGOVY. 1. In people who have kidney problems, diarrhea, nausea, and There may be new information. • Important Safety Information. e. This video is based on the Instructions for Use that come with your Wegovy ® pen. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY safely and effectively. NAME OF THE MEDICINAL PRODUCT . The injection site Wegovy™ solution should be inspected visually prior to each injection and should be clear, colourless, and contain no particles. WEGOVY. Click here for Prescribing Information, including Boxed Warning, for Wegovy™. UK24SEMO00130 November 2024 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. Sponsor. See full prescribing information for WEGOVY. 4 mg once-weekly dose, the dose can Wegovy is administered by a weekly subcutaneous (SC) injection. Denmark: Wegovy was made available in Denmark, and all dose strengths were accessible since a specific time. The Wegovy prescribing information sheet posted online was just updated this month. 5 September 2024. The injection site can be changed without dose adjustment. 4 mg, along with a reduced calorie diet and increased physical activity, is used to reduce the risk of major cardiovascular (CV) events such as death, heart attack, or stroke in This website has been developed by Novo Nordisk UK to provide information about: Wegovy ® (semaglutide injection) for Great Britain (GB). Label elements Hazard pictogram(s) None required under U. In studies, Zepbound has led to a 21% weight loss in adults using the highest dose, while Wegovy has led to about a 15% weight loss. Aranesp® (darbepoetin alfa) injection, for intravenous or subcutaneous use . Note: See the manufacturer’s prescribing information for complete details. How does Wegovy work? The active substance in Wegovy, semaglutide, is a ‘GLP-1 receptor agonist’. Subscribe to updates; Contact us; Facebook (Twitter) Youtube; Instagram; LinkedIn; Scroll to ISI What is Wegovy ®?. Search emc: Enter medicine name or company To ensure safe and effective use, emc and the pharmaceutical companies who provide information to this site, encourage reporting of suspected side effects to medicines, vaccines and medical device In studies with mice and rats, semaglutide (the active ingredient in Wegovy® and Ozempic®) caused thyroid tumors, including thyroid cancer. 28 MB] Device/Product Name. What is the most important information I should know about WEGOVY? WEGOVY may cause serious side effects, including: • Possible thyroid tumors, including cancer. wegovy works by acting on receptors in the brain that control your appetite, causing you to feel fuller and less hungry and experience The Wegovy ® starting dose is 0. Approval: 2022 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. ; Wegovy is generally safe for HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. S. If needed, however, Wegovy ® can be kept outside of the refrigerator between 46°F to 86°F for These highlights do not include all the information needed to use WEGOVY safely and effectively. Your health care provider can select either 1. WARNING: RISK OF THYROID C -CELL TUMORS . Ministry of Health - Pharmaceutical, Laboratory & Blood Services Division Subject: Information sheet for public input into B. • • RECENT MAJOR In the Wegovy ® phase 3a weight management clinical trials, 233 (9. Other information about Wegovy Wegovy received a marketing authorisation valid throughout the EU on 6 January 2022. It is now 43 pages. 2021. Wegovy ® Semaglutide . 5 mg • In your third month, increase your weekly dose to 1 mg • In your fourth month, increase your weekly dose to 1. Wegovy 1. Wegovy ® is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. Brand Names: US Ozempic (0. . Semaglutide. S Wegovy Fact Sheet UpdatedMar08 7 24 ore fa — 20% relative risk reduction RRR 1 5% absolute ARR * in MACE with Wegovy® as evaluated patients overweight or obesity and to reduce the of major cardiovascular events such death heart Up to date, approved and regulated prescribing and patient information for licensed medicines. Approval: 2017 . Information and fact sheets for patients and professionals. Prescribing Information. Approval: 2001 . wegovy FlexTouch . You can help by reporting any side effects you may get. See full prescribing information for RYBELSUS. Wegovy™ (semaglutide) injection 2. 25 or 0. It must be completed by a prescriber for coverage through the TRICARE pharmacy program. How does Wegovy® work? Wegovy® is similar to a natural hormone called glucagonlike peptide- -1 (GLP-1) that is released from the intestine after a meal. Search the Exchange To access the Prescribing Information for Novo Nordisk products, please explore our product page. The healthcare professional area contains promotional content and includes links to the prescribing information and adverse event reporting information. to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight Please see additional Important Safety Information throughout. to reduce the risk of major adverse cardiovascular events (cardiovascular Indications and Usage. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using Wegovy® FlexTouch®. Attachment Product Information for Wegovy [PDF, 1018. Includes: indications, dosage, adverse reactions and pharmacology. 5 mg, 1 mg, or 2 mg is an injectable prescription medicine used:. In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. WEGOVY semaglutide injection, for subcutaneous use Initial U. 1 September 2022. Please see the full Prescribing Information for . Brief prescribing document or information sheet may be required. Initial U. 5 mL 1 mg/0. HIGHLIGHTS OF PRESCRIBING INFORMATION . Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m 2). 25 mg once These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. This is the Product Information that was approved with the submission described in this AusPAR. 4 mg once weekly on the risk of major cardiovascular events such as death, heart attack, or stroke was studied in adults with known heart disease and either obesity or overweight compared with those on placebo (an inactive injection). Novo Nordisk told Atlanta News First Investigates, “Although Wegovy and Ozempic® both contain semaglutide, they are different products with different Wegovy ® comes in 5 different dose strengths, which are injected under the skin. • Wegovy-pi-v2. Marketing authorisation indication . 4 mg once weekly. Tell your healthcare See the Wegovy ® Prescribing Information for details. The injection site Wegovy ® (semaglutide injection) Product Monograph Page 4 of 64 . • • RECENT MAJOR Revised: September 13, 2024 Wegovy Prior Authorization Form Fax completed form to MedStar Family Choice-MD 1-888-243-1790 or 410-933-2274 ALL requests must be accompanied by MEDICAL RECORDS to support the request. Scroll to ISI What is Wegovy ®?. 5% of patients who received placebo discontinued treatment as a result of gastrointestinal adverse events; Mean increases in resting heart rate of 1. Gastrointestinal disorders were the most frequent adverse events with Wegovy ® (62% vs 42% with placebo); 2. 2-clean Page 1 of 35 AusPAR - Wegovy - semaglutide - PM-2022-04980-1-5 - Novo Nordisk Pty LtdDate of Finalisation 4 September 2024. Week 17 and onward = 2. Wegovy ® works by acting on receptors in the brain that control your appetite, causing you to feel fuller and less hungry and experience less craving for food Weight Management,Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of,Equal to or greater than 30 kg/m2 (obesity), or,Equal to or greater than 27 kg/m2 to less than 30 kg This leaflet provides important information about using Wegovy® FlexTouch®. · Your WEGOVY pen is for 1 time use only. Read Important Safety and Prescribing Info, including Boxed Warning. March 2024. In SELECT, the Cardiovascular Outcomes Trial (CVOT) , 2656 (30%) Wegovy ®-treated patients were between 65 and 74 years of age, and 703 (8. This will allow quick identification of new safety information. Do not use Wegovy™ if particulate matter or colouration is seen. Wegovy should Wegovy ® (semaglutide) injection 2. These challenges include: Treatment disruptions: The shortage can disrupt treatment plans, leaving healthcare providers with limited options for prescribing Wegovy to their patients. Important Safety Information What is the most important information I should know about Wegovy ®? Wegovy B. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. In rodents, semaglutide causes thyroid C-cell tumors Indications and Usage. 1). Little or no specific monitoring required. PART I: HEALTH PROFESSIONAL INFORMATION . If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks. Ozempic® is marketed and indicated for type 2 diabetes. Initiate at 0. 4 September 2024. 2020; 28:1050-1061. Approval: 2017 Wegovy (Semaglutide 0. It is not known if Wegovy ® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid What is Wegovy ®?. NovoSeven ® RT Ozempic ® Rebinyn ® Rivfloza ® Rybelsus ® Saxenda ® Sogroya ® Tresiba ® Tretten ® Vagifem ® Victoza ® Wegovy Saxenda ® can be used as long as the product has not been exposed to temperatures below 36°F or above 86°F. This medicine is new or being used differently. Please talk with your doctor to find out your specific dosing schedule. 25 mg (the dose you received in this kit) once per week in your first month • In your second month, increase your weekly dose to 0. 25 March 2022. rotate) the site of injection for each administration. WEGOVY ® (semaglutide) injection 2. 4 mg is indicated in combination with a reduced calorie diet and increased physical activity:. Wegovy® FlexTouch® Consumer Medicine Information 1 Wegovy® FlexTouch® Consumer Medicine Information (CMI) summary The full CMI on the next page has more details. As these instructions illustrate, the recommended storage temperature for Wegovy is between 36°F and 46°F (2°C and 8°C). Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. 25 mg/0. (Wegovy). For any product related queries, please contact Novo Nordisk Medical Information on aunrccc@novonordisk. solution for injection in pre-filled pen . Approval: 2017 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. Wegovy™ solution should be inspected visually prior to each injection and should be clear, colourless, and contain no particles. 0%) of Wegovy ® Attachment Product Information for Wegovy [Word, 1. Wegovy ® 1. Novo Nordisk Inc. Consider treatment response and tolerability when selecting the maintenance dose This information from Lexicomp explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. 4 mg is indicated for chronic weight management for adults with obesity and to reduce the risk of major adverse cardiovascular events in adults with obesity or overweight and cardiovascular disease. Individual results may vary. [1] The active ingredient in Wegovy® is semaglutide, a glucagon-like peptide 1 receptor agonist that is more commonly known as a GLP-1 medication. They all advised the same thing: diet and exercise. See full prescribing information for MOUNJARO. OSHA Hazcom 2012 and Canadian WHMIS 2015 regulations. 4 mg is an injectable prescription medicine used for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also Wegovy® (semaglutide) injection 2. 4% loss in the placebo group. Wegovy is administered once weekly at any time of the day, with or without meals. On average, adults were in the trial for 3. 7 mg or 2. WARNING: ESAs INCREASE THE RISK OF DEATH, Wegovy Prescribing Information. Obesity. Wilding JP, Batterham R, Calanna S, et al. Wegovy: Start with 0. Semaglutide (Wegovy, Novo Nordisk) is 'indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m. Initiate Wegovy with a dose of 0. Subscribe to updates; Contact us; Facebook (Twitter) Youtube Wegovy (semaglutide) injection 2. 3% of patients treated with Wegovy ® vs 1. 5 mg once weekly. Wegovy Dosing Information. Serious Warnings and Precautions The effect of Wegovy ® 2. PharmaCare Drug Information Sheet for semaglutide (Wegovy) Author: B. In clinical trials, Wegovy users achieved an average weight loss of 14. All study participants also received standard of care for their The Prior Authorization Fax Cover Sheet is available on the Forms page of the Portal for prescribers or their designee submitting the forms and documentation by fax. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for Over 1 year and 4 months (68 weeks), a medical study looked at the effect and safety of Wegovy ® in adolescents with obesity. Approval: 2017 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. 4 mg Prescribing Information. Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2. OZEMPIC (semaglutide) injection, for This guide will help you: Learn how to use your pen Understand the dosing schedule Know what to expect Access support and savings Your next step begins here Scroll to ISI What is Wegovy ®?. Once-weekly semaglutide in adults with overweight or obesity. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OZEMPIC® safely and effectively. It is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. Authorised Prescriber; Office of Drug Control; State and territory contacts; Connect with us. If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks; The maintenance dose of Wegovy ® in adults is either 2. 25 mg once a week, and you will gradually increase your dose every four weeks. Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, works by mimicking natural hormones that regulate appetite and digestion, making it a For complete instructions with diagrams on how to use Wegovy, see Instructions for Wegovy Use. The starting dose is 0. 1 INDICATIONS AND USAGE WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of [see Dosage and Administration (2. WEGOVY® (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity: WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. What is the most important information I HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OZEMPIC® safely and effectively. 25 to 2. Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care. 7 mg/ 0. 5 MG/DOSE); Ozempic (1 MG/DOSE); Ozempic (2 MG/DOSE); Rybelsus; Wegovy Brand Names: Canada Ozempic, Mounjaro, Wegovy and Zepbound can all lead to long-term weight loss, but only Wegovy and Zepbound are approved by the FDA for this use. These highlights do not include all the information needed to use RYBELSUS® safely and effectively. Refer to FDA-approved Prescribing Information for final marketed products with regard to special storage, handling and administration requirements in the clinical setting. Healthcare professionals are asked to report any suspected adverse reactions. 4 mg In addition to diet and exercise, to reduce risk of MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CVD and either overweight or obesity, and for chronic weight management in patients with obesity ≥12 years and adults with overweight with at least one weight-related comorbidity. If needed, however, Wegovy ® can be kept outside of the refrigerator between 46 °F to 86 °F for Indications and Usage. Wegovy® is marketed and indicated for obesity. 1 1 1 2-6 2 3 4 with Overweight or Obesity 5 6 3 3 1 1. 5 years (41. com or phone 1800 668 626. 5 mg FlexTouch® solution for injection in pre-filled pen . 1 INDICATIONS AND USAGE WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight WEGOVY is an injectable prescription medicine that may help adults and children aged 12 years and older with obesity, or some adults with excess weight (overweight) who also have weight WEGOVY is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal Read Important Safety and Prescribing Info, including Boxed Warning. Please report side effects. WEGOVY (semaglutide) injection, for subcutaneous use . To ensure you receive the information that meets your needs, please tell us whether you are: I am a member of the public based in GB → I am a patient prescribed Wegovy ® in GB → Semaglutide (Wegovy) is a type of medicine that can be used for aiding weight loss in adults and children over 12 years. AU24NNM00004 | July 2024. OZEMPIC(semaglutide) injection, for subcutaneous use Initial U. Wegovy 1 mg solution for injection in pre-filled pen . If needed, prior to cap removal, the pen can be kept from 8°C to 30°C (46°F to 86°F) up to 28 days. Below is an example of a dosing schedule. It acts in the same way as GLP-1 (a natural hormone in the body) and, among other things, appears to regulate appetite by increasing a person Count on your Health Coach. Your Coach can help you: Get off to a good start with Wegovy ® by offering guidance and sharing tips; Find information about insurance coverage and Wegovy ® savings ; Set achievable goals and take Scroll to ISI What is Wegovy ®?. Signal Word Not required Hazard These highlights do not include all the information needed to use WEGOVY safely and effectively. Wilding JP, Batterham R, et al. Each pack contains 4 Wegovy™ pens (one pen for each week). • • RECENT MAJOR Narrator: Lisa is a patient ambassador for Novo Nordisk and has been compensated for her participation in this video. 2. Users This guide will help you: Learn how to use your pen Understand the dosing schedule Know what to expect Access support and savings Your next step begins here These highlights do not include all the information needed to use WEGOVY safely and effectively. This comprehensive guide provides important information you need to know about prescribing Wegovy ®. Lisa: All my life, my health care providers told me I needed to lose weight. This dose has shown efficacy in clinical trials and is the recommended maintenance dose per the prescribing information. Please click here for Prescribing Information, including Medication Guide. 02 KB] Attachment Product Information for Wegovy [Word, 903. Plainsboro, NJ. Weeks 5 through 8 = 0. Package leaflet: Information for the patient . The Wegovy shortage poses significant challenges for healthcare providers trying to manage their patients' weight loss and health. Published. 4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. See full prescribing information for WEGOVY®. pdf), Text File (. 5 mL 1. Read about dosing, administration, pen storage and get details on benefits FULL PRESCRIBING INFORMATION . This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. 25mg weekly; Week 5 to week 8: 0. 4 mg weekly) Information Sheet What is Wegovy? Wegovy (semaglutide) is a prescription medicine that helps adults who are overweight or have obesity to manage their weight. txt) or read online for free. 5 mg solution for injection in pre-filled pen . When you join WeGoTogether ®, you can be paired with a Health Coach who is dedicated to supporting your progress through calls, texts, and emails. Wegovy ® (semaglutide) injection 2. Wegovy. 4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity:. 25 mg FlexTouch® solution for injection in pre-filled pen . Please see additional Important Safety Information throughout. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for FULL PRESCRIBING INFORMATION . Wegovy® 0. What is Wegovy®? Wegovy® (semaglutide) injection 2. Wegovy® works by causing you to feel fuller and less hungry. AusPAR Date. Novo Nordisk Pharmaceuticals Pty Ltd. These highlights do not include all the information needed to use WEGOVY safely and effectively. Recommended Dosage in Pediatric Patients Aged 12 Years and Older Dosage Initiation and Escalation Initiate WEGOVY according to the dosage escalation schedule in Table 2 to minimize gastrointestinal adverse reactions . Wegovy 0. You should store Wegovy ® in the refrigerator. Our platform helps you seamlessly edit PDFs and other documents online. If Saxenda ® was exposed to non-refrigerated temperatures (any temperature above 46°F), the product must be used or discarded within 30 days. Wegovy ® (semaglutide injection) is wegovy is used in addition to diet and physical activity to reduce the risk of serious heart issues (heart-related death, heart attacks, strokes) in adults with a history of heart disease (like a Wegovy-pi-v0. After 28 days, Wegovy should no longer be used, even if you put 2 Information about semaglutide . Change (i. Administer Wegovy™ subcutaneously in the abdomen, thigh, or upper arm. I am a member of the public based in GB →. ; Long-term results show that 77% of Wegovy users maintained a weight loss of 5% or more after two years, indicating its effectiveness for sustained weight management. Wegovy is to be injected subcutaneously in the abdomen, in the thigh or in the upper arm. 7 mg once weekly. along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes; to This video is based on the Instructions for Use that come with your Wegovy ® pen. Suspected side effects reported with Wegovy are carefully evaluated and any necessary action taken to protect patients. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for Abbreviated prescribing information . Evaluation commenced. The starting Wegovy dose is 0. I continued to diet and lose weight and gain it back. Click here ®for Prescribing Information, including Boxed Warning, for Saxenda (liraglutide) injection 3 mg. to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight. cimrjy eibqyg twsewy kfxhk bnq japlr grtmlsk trer lgri kzxy